Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals develops PEDMARK, a medication to reduce platinum-induced ototoxicity in cancer patients receiving cisplatin-based chemotherapy.
8-KSep 17Latest SEC filing, period to Sep 17
Sep 17Latest story
September 2026